These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32108506)

  • 21. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T; Ramakrishnan R; Steiner G; Shachter NS
    J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity.
    Luo M; Liu A; Wang S; Wang T; Hu D; Wu S; Peng D
    Sci Rep; 2017 May; 7(1):2312. PubMed ID: 28539597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism.
    Luo M; Su X; Yi Y; Yang Y; Peng D
    Lipids Health Dis; 2018 Jul; 17(1):160. PubMed ID: 30021607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis.
    Han Y; Qi R; Liu G
    Biochem Biophys Res Commun; 2015 Jul; 462(4):420-5. PubMed ID: 25969427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.
    Sacks FM; Alaupovic P; Moye LA; Cole TG; Sussex B; Stampfer MJ; Pfeffer MA; Braunwald E
    Circulation; 2000 Oct; 102(16):1886-92. PubMed ID: 11034934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
    Hiukka A; Fruchart-Najib J; Leinonen E; Hilden H; Fruchart JC; Taskinen MR
    Diabetologia; 2005 Jun; 48(6):1207-15. PubMed ID: 15864534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein CIII links dyslipidemia with atherosclerosis.
    Kawakami A; Yoshida M
    J Atheroscler Thromb; 2009 Mar; 16(1):6-11. PubMed ID: 19262004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism.
    Fredenrich A
    Diabetes Metab; 1998 Dec; 24(6):490-5. PubMed ID: 9932215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome.
    van der Ham RL; Alizadeh Dehnavi R; Berbée JF; Putter H; de Roos A; Romijn JA; Rensen PC; Tamsma JT
    Diabetes Care; 2009 Jan; 32(1):184-6. PubMed ID: 18835943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.
    Kawakami A; Aikawa M; Libby P; Alcaide P; Luscinskas FW; Sacks FM
    Circulation; 2006 Feb; 113(5):691-700. PubMed ID: 16461842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
    Chiuve SE; Martin LA; Campos H; Sacks FM
    J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia.
    Caron S; Verrijken A; Mertens I; Samanez CH; Mautino G; Haas JT; Duran-Sandoval D; Prawitt J; Francque S; Vallez E; Muhr-Tailleux A; Berard I; Kuipers F; Kuivenhoven JA; Biddinger SB; Taskinen MR; Van Gaal L; Staels B
    Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):513-9. PubMed ID: 21183731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.
    Kassai A; Muniyappa R; Levenson AE; Walter MF; Abel BS; Ring M; Taylor SI; Biddinger SB; Skarulis MC; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1790-7. PubMed ID: 26900642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Positive Association between Plasma Myristic Acid and ApoCIII Concentrations in Cardiovascular Disease Patients Is Supported by the Effects of Myristic Acid in HepG2 Cells.
    Olivieri O; Speziali G; Castagna A; Pattini P; Udali S; Pizzolo F; Liesinger L; Gindlhuber J; Tomin T; Schittmayer M; Birner-Gruenberger R; Cecconi D; Girelli D; Friso S; Martinelli N
    J Nutr; 2020 Oct; 150(10):2707-2715. PubMed ID: 32710763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
    van Capelleveen JC; Lee SR; Verbeek R; Kastelein JJP; Wareham NJ; Stroes ESG; Hovingh GK; Khaw KT; Boekholdt SM; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(6):1493-1501.e11. PubMed ID: 30249512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.
    Hu ZJ; Ren LP; Wang C; Liu B; Song GY
    Exp Ther Med; 2014 Sep; 8(3):951-956. PubMed ID: 25120629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.